93 related articles for article (PubMed ID: 6223572)
21. The interaction of glycoprotein C of herpes simplex virus types 1 and 2 with the alternative complement pathway.
Hung SL; Peng C; Kostavasili I; Friedman HM; Lambris JD; Eisenberg RJ; Cohen GH
Virology; 1994 Sep; 203(2):299-312. PubMed ID: 8053154
[TBL] [Abstract][Full Text] [Related]
22. [Binding of activated C3b component with complement effector].
Kozlov LV; Rostovtseva LI; Lomaka TS; Sutovskaia NS
Bioorg Khim; 1985 Jun; 11(6):762-8. PubMed ID: 3849970
[TBL] [Abstract][Full Text] [Related]
23. Investigation of the mechanisms of anti-complement activity in Ixodes ricinus ticks.
Lawrie CH; Sim RB; Nuttall PA
Mol Immunol; 2005 Jan; 42(1):31-8. PubMed ID: 15488941
[TBL] [Abstract][Full Text] [Related]
24. Deviated lysis: lysis of unsensitized cells by complement. V. Generation of the activity of low pH or low ionic strength.
Rother U; Hänsch G; Rauterberg EW; Jungfer H; Rother K
Z Immunitatsforsch Immunobiol; 1978 Dec; 155(2):118-29. PubMed ID: 34275
[TBL] [Abstract][Full Text] [Related]
25. Isolation and identification of the third component of complement of Japanese quails.
Kai C; Yoshikawa Y; Yamanouchi K; Okada H
J Immunol; 1983 Jun; 130(6):2814-20. PubMed ID: 6343485
[TBL] [Abstract][Full Text] [Related]
26. Accelerated nonproteolytic cleavage of C3 in plasma from patients with primary biliary cirrhosis.
Lindgren S
J Lab Clin Med; 1989 Dec; 114(6):655-61. PubMed ID: 2531785
[TBL] [Abstract][Full Text] [Related]
27. CR2 is the primary acceptor site for C3 during alternative pathway activation of complement on human peripheral B lymphocytes.
Marquart HV; Svehag SE; Leslie RG
J Immunol; 1994 Jul; 153(1):307-15. PubMed ID: 7515925
[TBL] [Abstract][Full Text] [Related]
28. Complement (C3b) interaction with the human granulocyte receptor: correlation of binding of fluid-phase radiolabeled ligand with histaminase release.
Melamed J; Arnaout MA; Colten HR
J Immunol; 1982 May; 128(5):2313-8. PubMed ID: 6801135
[TBL] [Abstract][Full Text] [Related]
29. A 34-amino acid peptide of the third component of complement mediates properdin binding.
Daoudaki ME; Becherer JD; Lambris JD
J Immunol; 1988 Mar; 140(5):1577-80. PubMed ID: 3279119
[TBL] [Abstract][Full Text] [Related]
30. The interaction of C5 with C3b in free solution: a sufficient condition for cleavage by a fluid phase C3/C5 convertase.
Isenman DE; Podack ER; Cooper NR
J Immunol; 1980 Jan; 124(1):326-31. PubMed ID: 7350230
[TBL] [Abstract][Full Text] [Related]
31. Evidence for restriction of the ability of complement to lyse homologous erythrocytes.
Houle JJ; Hoffmann EM
J Immunol; 1984 Sep; 133(3):1444-52. PubMed ID: 6430999
[TBL] [Abstract][Full Text] [Related]
32. Binding of C3 fragments to the Trypanosoma cruzi surface in the absence of specific antibodies and without activation of the complement cascade.
Krettli AU; Pontes de Carvalho LC
Clin Exp Immunol; 1985 Nov; 62(2):270-7. PubMed ID: 3910312
[TBL] [Abstract][Full Text] [Related]
33. Characterization of the human complement (c3b) receptor with a fluid phase C3b dimer.
Arnaout MA; Melamed J; Tack BF; Colten HR
J Immunol; 1981 Oct; 127(4):1348-54. PubMed ID: 7276561
[TBL] [Abstract][Full Text] [Related]
34. Interaction of C3 with antigen-antibody complexes in the process of solubilization of immune precipitates.
Takata Y; Tamura N; Fujita T
J Immunol; 1984 May; 132(5):2531-7. PubMed ID: 6232320
[TBL] [Abstract][Full Text] [Related]
35. Disruption of the internal thioester bond in the third component of complement (C3) results in the exposure of neodeterminants also present on activation products of C3. An analysis with monoclonal antibodies.
Hack CE; Paardekooper J; Smeenk RJ; Abbink J; Eerenberg AJ; Nuijens JH
J Immunol; 1988 Sep; 141(5):1602-9. PubMed ID: 2457622
[TBL] [Abstract][Full Text] [Related]
36. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
[TBL] [Abstract][Full Text] [Related]
37. A study of the breakdown of the third component of human complement (C3).
Fontaine M; Rivat C
Ann Immunol (Paris); 1979; 130C(3):349-66. PubMed ID: 475341
[TBL] [Abstract][Full Text] [Related]
38. Partial characterization of physiologically generated C3 components expressing C3d but not C3c epitopes.
Siersted HC; Jensenius JC; Svehag SE; Brandslund I
J Clin Lab Immunol; 1983 Dec; 12(4):201-8. PubMed ID: 6198522
[TBL] [Abstract][Full Text] [Related]
39. Coupling of C3b to erythrocytes by disulfide bond formation: preparation of EC3b for hemolytic and complement receptor assays.
Lambris JD; Scheiner O; Schulz TF; Alsenz J; Dierich MP
J Immunol Methods; 1983 Dec; 65(3):277-83. PubMed ID: 6197481
[TBL] [Abstract][Full Text] [Related]
40. Complement C3b receptors on erythrocytes, circulating immune complexes, and complement C3 split products in patients with primary Sjögren's syndrome.
Thomsen BS; Oxholm P; Manthorpe R; Nielsen H
Arthritis Rheum; 1986 Jul; 29(7):857-62. PubMed ID: 2943291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
